Roy Maute
June 12, 2023
Dr. Maute is a scientist and biotechnology entrepreneur, and is a co-founder of Pheast Therapeutics. He leads the company as Chief Executive Officer. Prior to Pheast, he led the Translational Science and Biomarker team at Forty Seven Inc. and following acquisition by Gilead Sciences in 2020, continued to support the anti-CD47 magrolimab and anti-SIRPA programs as Biomarker lead. Dr. Maute was also a co-founder of Ab Initio Biotherapeutics, and led the research team as Head of Biology from founding in 2015 until acquisition by Ligand Pharmaceuticals in 2019. He trained as a postdoctoral fellow in the laboratory of Dr. Irving Weissman at Stanford University School of Medicine. Dr. Maute received his Ph.D. in genetics from Columbia University and a B.A. in molecular and cell biology from UC Berkeley.